Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RPTX Stock Forecast 2025-2026
$1.32
Current Price
$57.05M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RPTX Price Targets
+504.7%
To High Target of $8.00
+391.3%
To Median Target of $6.50
+277.9%
To Low Target of $5.00
RPTX Price Momentum
-2.9%
1 Week Change
+10.0%
1 Month Change
-62.8%
1 Year Change
+0.8%
Year-to-Date Change
-69.2%
From 52W High of $4.29
+48.7%
From 52W Low of $0.89
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Repare (RPTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RPTX and similar high-potential opportunities.
Latest RPTX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, RPTX has a neutral consensus with a median price target of $6.50 (ranging from $5.00 to $8.00). The overall analyst rating is Buy (7.5/10). Currently trading at $1.32, the median forecast implies a 391.3% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 277.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RPTX Analyst Ratings
2
Buy
2
Hold
0
Sell
RPTX Price Target Range
Low
$5.00
Average
$6.50
High
$8.00
Current: $1.32
Latest RPTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RPTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $5.00 |
| Dec 13, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $4.00 |
| Dec 13, 2024 | LifeSci Capital | Charles Zhu | Market Perform | Downgrade | $0.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Sep 23, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| May 30, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Mar 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Feb 21, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $10.00 |
| Nov 20, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| Oct 16, 2023 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $25.00 |
| Sep 25, 2023 | Stifel | Benjamin Burnett | Buy | Maintains | $17.00 |
| Aug 17, 2023 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Jun 9, 2023 | Stifel | Benjamin Burnett | Buy | Upgrade | $16.00 |
| Jun 9, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $26.00 |
| Apr 27, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| Mar 17, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
Repare Therapeutics Inc. (RPTX) Competitors
The following stocks are similar to Repare based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Repare Therapeutics Inc. (RPTX) Financial Data
Repare Therapeutics Inc. has a market capitalization of $57.05M with a P/E ratio of 0.0x. The company generates $1.07M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -12,197.8% and return on equity of -71.6%.
Valuation Metrics
Market Cap
$57.05M
Enterprise Value
$-65,810,436
P/E Ratio
0.0x
PEG Ratio
-0.4x
Price/Sales
53.2x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-12,197.8%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+218.9%
Current Ratio
7.4x
Debt/Equity
1.1x
ROE
-71.6%
ROA
-40.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Repare Therapeutics Inc. (RPTX) Business Model
About Repare Therapeutics Inc.
What They Do
Develops innovative cancer therapeutics through precision medicine.
Business Model
Repare Therapeutics Inc. generates revenue by developing and advancing targeted cancer therapies that exploit genetic vulnerabilities in cancer cells. Their business model focuses on research and development investments in synthetic lethality, enabling them to create personalized treatment options that can effectively kill cancer cells while preserving healthy tissue.
Additional Information
The company operates within the biopharmaceutical sector and collaborates with global scientific experts, positioning itself to contribute significantly to personalized medicine and potential breakthroughs in cancer treatment. Its foundation in advanced genomic technologies underscores its commitment to innovation in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
129
CEO
Mr. Steve Forte CPA
Country
Canada
IPO Year
2020
Website
www.reparerx.comRepare Therapeutics Inc. (RPTX) Latest News & Analysis
Latest News
Quick Summary
Repare Therapeutics (Nasdaq: RPTX) reported Q1 2025 financial results, focusing on long-term shareholder value through partnerships and advancing their pipeline programs.
Why It Matters
Repare Therapeutics' Q1 2025 financial results indicate progress in their pipeline and partnerships, influencing future growth potential and shareholder value.
Source: Business Wire
Market Sentiment:
Neutral
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
17 days ago
Quick Summary
Repare Therapeutics has out-licensed its discovery platforms and related IP to DCx Biotherapeutics, a new Canadian biotech focused on precision drug conjugates, backed by Amplitude Ventures.
Why It Matters
Repare's out-licensing deal indicates strategic partnerships and potential revenue streams, signaling confidence in its technology and opening pathways for innovation in precision oncology.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DCx Biotherapeutics has signed an agreement with Repare Therapeutics to in-license a discovery platform, acquire lab facilities in Montreal, and obtain laboratory equipment.
Why It Matters
The agreement enhances DCx Biotherapeutics' capabilities and resources, potentially driving innovation and growth, which may boost investor confidence and influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
23 days ago
Quick Summary
Repare Therapeutics (Nasdaq: RPTX) announced the acceptance of two abstracts for mini-oral and four for poster presentations at the AACR Annual Meeting, scheduled for April 25-30, 2025.
Why It Matters
Repare Therapeutics' acceptance of multiple abstracts at a prominent cancer research conference highlights its ongoing innovation and may enhance its visibility and credibility in the oncology market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Repare Therapeutics appointed Steve Forte as President and CEO, effective April 11, 2025, while he continues as CFO. Lloyd M. Segal has resigned from the company.
Why It Matters
Leadership changes can impact a company's strategic direction and investor confidence. Steve Forte's dual role may signal continuity and stability, potentially influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Repare Therapeutics (RPTX) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Why It Matters
Repare Therapeutics' upgrade to Zacks Rank #2 indicates strong earnings potential, suggesting a likely increase in stock value and attracting bullish investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About RPTX Stock
What is Repare Therapeutics Inc.'s (RPTX) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Repare Therapeutics Inc. (RPTX) has a median price target of $6.50. The highest price target is $8.00 and the lowest is $5.00.
Is RPTX stock a good investment in 2025?
According to current analyst ratings, RPTX has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RPTX stock?
Wall Street analysts predict RPTX stock could reach $6.50 in the next 12 months. This represents a 391.3% increase from the current price of $1.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Repare Therapeutics Inc.'s business model?
Repare Therapeutics Inc. generates revenue by developing and advancing targeted cancer therapies that exploit genetic vulnerabilities in cancer cells. Their business model focuses on research and development investments in synthetic lethality, enabling them to create personalized treatment options that can effectively kill cancer cells while preserving healthy tissue.
What is the highest forecasted price for RPTX Repare Therapeutics Inc.?
The highest price target for RPTX is $8.00 from at , which represents a 504.7% increase from the current price of $1.32.
What is the lowest forecasted price for RPTX Repare Therapeutics Inc.?
The lowest price target for RPTX is $5.00 from Robert Burns at HC Wainwright & Co., which represents a 277.9% increase from the current price of $1.32.
What is the overall RPTX consensus from analysts for Repare Therapeutics Inc.?
The overall analyst consensus for RPTX is neutral. Out of 6 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $6.50.
How accurate are RPTX stock price projections?
Stock price projections, including those for Repare Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 6:48 PM UTC